Filgotinib for moderately to severely active ulcerative colitis - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Expert Review of Gastroenterology & Hepatology Année : 2022

Filgotinib for moderately to severely active ulcerative colitis

Résumé

Filgotinib is an oral Janus kinase type 1 (JAK1) selective inhibitor with demonstrated efficacy and safety in ulcerative colitis (UC). The aim of this review is to summarize the available evidence on pharmacological characteristics, efficacy, and safety of filgotinib in UC.
Fichier non déposé

Dates et versions

hal-04167928 , version 1 (21-07-2023)

Identifiants

Citer

Alessandro Mannucci, Ferdinando d'Amico, Ahmad El Saadi, Laurent Peyrin‐biroulet, Silvio Danese. Filgotinib for moderately to severely active ulcerative colitis. Expert Review of Gastroenterology & Hepatology, 2022, 16 (10), pp.927-940. ⟨10.1080/17474124.2022.2138857⟩. ⟨hal-04167928⟩
5 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More